Title:
腫瘍の診断及び治療におけるＦＳＨホルモン受容体のリガンド
Document Type and Number:
Japanese Patent JP7226803
Kind Code:
B2
Abstract:
The present invention relates to ligands of the follicle stimulating hormone (FSH) receptor for use in the diagnosis and treatment of tumors.
Inventors:
Carpi, Andrea
Maseo, fabio
Dal Monte, Renzo
Maseo, fabio
Dal Monte, Renzo
Application Number:
JP2019540719A
Publication Date:
February 21, 2023
Filing Date:
October 10, 2017
Export Citation:
Assignee:
ONCOGREEN THERAPEUTICS SA
International Classes:
C12N15/16; A61K38/24; A61P35/00; A61P35/04; C07K14/59; C12N5/04; C12N15/74; C12N15/82; C12P21/02
Domestic Patent References:
| JP2016506373A |
Other References:
rHu FSH-beta,ABR[online],2016年08月06日,URL: https://web.archive.org/web/20160806105921/http://www.abres.it/product.php,[retrieved on 9/13/2021]
Zhang, X. et al.,Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma,Int. J. Pharm.,2013年,Vol. 453(2),pp. 498-505
P01225 (FSHB_HUMAN),UniProt[online],1989年10月01日,URL: https://www.uniprot.org/uniprot/P01225,[retrieved on 9/13/2021]
Zhang, X. et al.,Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma,Int. J. Pharm.,2013年,Vol. 453(2),pp. 498-505
P01225 (FSHB_HUMAN),UniProt[online],1989年10月01日,URL: https://www.uniprot.org/uniprot/P01225,[retrieved on 9/13/2021]
Attorney, Agent or Firm:
Patent Attorney Corporation Hiroe Associates Patent Office